Publications

Yi-ying Chou

Most Recent Peer-Reviewed Publication


Behzadi MA, Choi A, Duehr J, Feyznezhad R, Upadhyay C, Schotsaert M, Palese P, Nachbagauer R. A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro. Sci Rep. 2020;10(1):9750. Published 2020 Jun 16. doi:10.1038/s41598-020-66600-x. PMID:32546721


Zheng A, Sun W, Xiong X, Freyn AW, Peukes J, Stromeier S, Nachbagauer R, Briggs JAG, Krammer F, Palese P. Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals [published online ahead of print, 2020 Jun 3]. J Virol. 2020;JVI.00742-20. doi:10.1128/JVI.00742-20


Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D, Krammer F, Coughlan L, Palese P, Pardi N, Nachbagauer R. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol Ther. 2020 Apr 19:S1525-0016(20)30199-4. doi: 10.1016/j.ymthe.2020.04.018. Online ahead of print.PMID: 32359470


Calisher C, Carroll D, Colwell R, Corley RB, Daszak P, Drosten C, Enjuanes L, Farrar J, Field H, Golding J, Gorbalenya A, Haagmans B, Hughes JM, Karesh WB, Keusch GT, Lam SK, Lubroth J, Mackenzie JS, Madoff L, Mazet J, Palese P, Perlman S, Poon L, Roizman B, Saif L, Subbarao K, Turner M. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. Lancet. 2020 Mar 7;395(10226):e42-e43. doi: 10.1016/S0140-6736(20)30418-9. Epub 2020 Feb 19.PMID: 32087122


Mullokandov G, Vijayakumar G, Leon P, Henry C, Wilson PC, Krammer F, Palese P, Brown BD.High-complexity extracellular barcoding using a viral hemagglutinin. Proc Natl Acad Sci U S A. 2020 Feb 11;117(6):2767-2769. doi: 10.1073/pnas.1919182117. Epub 2020 Jan 27.PMID: 31988118


Nachbagauer R, Salaun B, Stadlbauer D, Behzadi MA, Friel D, Rajabhathor A, Choi A, Albrecht RA, Debois M, García-Sastre A, Rouxel RN, Sun W, Palese P, Mallett CP, Innis BL, Krammer F, Claeys C. Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. NPJ Vaccines. 2019 Dec 6;4:51. doi: 10.1038/s41541-019-0147-z. eCollection 2019.PMID: 31839997


Vijayakumar G, McCroskery S, Palese P. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. J Virol. 2020 Jan 17;94(3):e01677-19. doi: 10.1128/JVI.01677-19. Print 2020 Jan 17.PMID: 31694938


Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.  EBioMedicine. 2019 Nov;49:96-105. doi: 10.1016/j.ebiom.2019.10.032. Epub 2019 Oct 29.PMID: 31676387


Bernstein DI, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J, Wilson PC, Solórzano A, Van der Wielen M, Walter EB, Albrecht RA, Buschle KN, Chen YQ, Claeys C, Dickey M, Dugan HL, Ermler ME, Freeman D, Gao M, Gast C, Guthmiller JJ, Hai R, Henry C, Lan LY, McNeal M, Palm AE, Shaw DG, Stamper CT, Sun W, Sutton V, Tepora ME, Wahid R, Wenzel H, Wohlbold TJ, Innis BL, García-Sastre A, Palese P, Krammer F. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020 Jan;20(1):80-91. doi: 10.1016/S1473-3099(19)30393-7. Epub 2019 Oct 17.PMID: 31630990


Nachbagauer R, Palese P. Is a Universal Influenza Virus Vaccine Possible. Annu Rev Med. 2019 Oct 10. doi: 10.1146/annurev-med-120617-041310. [Epub ahead of print] PubMed PMID: 31600454.